172 related articles for article (PubMed ID: 19505376)
21. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
22. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies.
Vena GA; Cassano N; Piaserico S; Conti A; Girolomoni G
Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):901-6. PubMed ID: 22686544
[TBL] [Abstract][Full Text] [Related]
24. Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions.
de Boer OJ; van der Loos CM; Hamerlinck F; Bos JD; Das PK
Arch Dermatol Res; 1994; 286(2):87-96. PubMed ID: 7512323
[TBL] [Abstract][Full Text] [Related]
25. A global approach to psoriatic patients through PASI score and Skindex-29.
Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
[TBL] [Abstract][Full Text] [Related]
26. Biological agents and psoriatic epidermis: what are we ultimately targeting?
Heenen M; Simonart T
Dermatology; 2006; 212(4):321-3. PubMed ID: 16707880
[No Abstract] [Full Text] [Related]
27. TREM-1 as a potential therapeutic target in psoriasis.
Hyder LA; Gonzalez J; Harden JL; Johnson-Huang LM; Zaba LC; Pierson KC; Eungdamrong NJ; Lentini T; Gulati N; Fuentes-Duculan J; Suárez-Fariñas M; Lowes MA
J Invest Dermatol; 2013 Jul; 133(7):1742-51. PubMed ID: 23407402
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
Lizzul PF; Aphale A; Malaviya R; Sun Y; Masud S; Dombrovskiy V; Gottlieb AB
J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
[TBL] [Abstract][Full Text] [Related]
30. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
31. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
[TBL] [Abstract][Full Text] [Related]
32. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A
Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229
[TBL] [Abstract][Full Text] [Related]
33. Etanercept for the treatment of psoriasis.
Bissonnette R
Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060
[TBL] [Abstract][Full Text] [Related]
34. Specific roles for dendritic cell subsets during initiation and progression of psoriasis.
Glitzner E; Korosec A; Brunner PM; Drobits B; Amberg N; Schonthaler HB; Kopp T; Wagner EF; Stingl G; Holcmann M; Sibilia M
EMBO Mol Med; 2014 Oct; 6(10):1312-27. PubMed ID: 25216727
[TBL] [Abstract][Full Text] [Related]
35. Severe generalized exanthema due to etanercept given for severe plaque psoriasis.
Gonzalo-Garijo MA; Pérez-Calderón R; de Argila Fernández-Durán D
Ann Allergy Asthma Immunol; 2008 Jun; 100(6):621-2. PubMed ID: 18592833
[No Abstract] [Full Text] [Related]
36. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
[TBL] [Abstract][Full Text] [Related]
37. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.
Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 May; 158(5):1098-106. PubMed ID: 18384440
[TBL] [Abstract][Full Text] [Related]
38. Etanercept provides a more physiological approach in the treatment of psoriasis.
Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs.
Kallimanis PG; Xenos K; Markantonis SL; Stavropoulos P; Margaroni G; Katsambas A; Avgerinou G
Clin Exp Dermatol; 2009 Jul; 34(5):582-6. PubMed ID: 19094132
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
